ABVC BioPharma closes $1.75M registered direct offering of common stock and pre-funded warrants

ABVC BIOPHARMA, INC.

Offering of 500,000 shares/pre-funded warrants at $3.50/share to a single institutional investor.
Gross proceeds of $1.75 million before fees; net proceeds for R&D, working capital, and debt repayment.
Wilmington Capital Securities acted as placement agent; offering through existing shelf registration.
Closing occurred July 31, 2023, with all conditions satisfied.

item 1.01 item 3.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

ABVC BIOPHARMA, INC. entered into SPA with a certain institutional investor (effective 2023-07-27).

Action: entry
Agreement: equity purchase
Counterparty: a certain institutional investor
Effective: 2023-07-27

Exact text from the filing

the Company entered into certain securities purchase agreement, dated July 27, 2023 (the “ SPA ”), with a certain institutional investor (the “ Purchaser ”).

View on SEC.gov

Browse all material agreements →

ABVC BIOPHARMA, INC. filing history →

Source: SEC EDGAR

accession 0001213900-23-061038

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.